tert-butyl {2-[7-hydroxy-2-oxo-2H-chromen-4-yl]acetamido}ethylcarbamate | 911290-41-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: tert-butyl {2-[7-hydroxy-2-oxo-2H-chromen-4-yl]acetamido}ethylcarbamate
• 英文别名: tert-butyl 2-{[(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl]amino}ethylcarbamate；4-[[(2-tert-butoxycarbonylaminoethyl)aminocarbonyl]methyl]-7-hydroxy-2H-chromen-2-one；4-[[(2-tert-Butoxycarbonylaminoethyl)aminocarbonyl]methyl]-7-hydroxy-2H-chromen-2-one；tert-butyl N-[2-[[2-(7-hydroxy-2-oxochromen-4-yl)acetyl]amino]ethyl]carbamate
• CAS: 911290-41-0
• 化学式: C₁₈H₂₂N₂O₆
• 分子量: 362.382
• InChiKey: PAEBPICFAMBUOB-UHFFFAOYSA-N

物化性质

• 沸点：
  652.4±55.0 °C(Predicted)
• 密度：
  1.271±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl {2-[7-hydroxy-2-oxo-2H-chromen-4-yl]acetamido}ethylcarbamate 在 三苯基膦 、 三氟乙酸 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 18.25h， 生成 N-(2-aminoethyl)-2-{7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl}acetamide
  参考文献：
  名称：

  WO2006/102958

  摘要：

  公开号：
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 1-羟基苯并三唑 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 tert-butyl {2-[7-hydroxy-2-oxo-2H-chromen-4-yl]acetamido}ethylcarbamate
  参考文献：
  名称：

  Design, synthesis and biological evaluation of coumarin coupled nitroimidazoles as potential imaging agents

  摘要：

  实体肿瘤与正常组织相比，含有缺氧区域。硝基咪唑类化合物已显示出针对不同类型癌症的巨大潜力。

  DOI：

  10.1039/c5ra17907f

文献信息

• Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives
  申请人：Carotti Angelo

  公开号：US20090005436A1

  公开（公告）日：2009-01-01

  This invention is related to novel aminoalkyl- and amidoalkyl-benzopyran derivatives of the following general formula (I) wherein: the group is a substituent in position 6 or 7 wherein: R is an aromatic mono- or bi-cyclic carbocyclic ring or a mono- or bi-cyclic heterocyclic ring radical, said rings being optionally substituted by one or two substituents selected from (C 1 -C 5 ) straight or branched alkyl, (C 1 -C 5 ) straight or branched alkoxy, hydroxy, halogen and trifluoromethyl; m is zero or an integer from 1 to 3; n, p, R 1 and R 2 are as herein indicated and R 3 and R 4 are both hydrogen or taken together represent an oxygen atom, and the pharmaceutically acceptable salts thereof. The compounds that are active as selective and reversible MAO-B inhibitors in vitro and in vivo, are useful as medicaments for the prevention and the treatment of CNS degenerative disorders.

  本发明涉及以下通式（I）的新型氨基烷基和酰胺烷基苯并吡喃衍生物： 其中：基团是6或7位的取代基，其中：R是芳香单环或双环碳环或单环或双环杂环基团，所述环可以选择地由一或两个取代基取代，所述取代基选择自（C1-C5）直链或支链烷基，（C1-C5）直链或支链烷氧基，羟基，卤素和三氟甲基；m为零或1至3的整数；n、p、R1和R2如本文所示，而R3和R4均为氢或一起代表氧原子，以及其药学上可接受的盐。 这些化合物在体外和体内作为选择性和可逆的MAO-B抑制剂具有活性，可用作预防和治疗中枢神经系统退行性疾病的药物。
• PROBE FOR iFRET AND USE THEREOF
  申请人：Chung Sang Jeon

  公开号：US20140242606A1

  公开（公告）日：2014-08-28

  The present invention relates to a probe for iFRET and use thereof. Specifically, the present invention relates to a novel probe for iFRET, a method for preparing the probe for iFRET, a method for searching a target protein-specific binding site or a molecule having the binding site using the probe for iFRET, and a method for imaging the target protein using the probe for iFRET. The probe for iFRET according to the present invention utilizes an amino acid in a protein as a fluorescent donor, unlike the conventional FRET method. Therefore, only one fluorescent material is used, and its emission wavelength is distinct from the intrinsic fluorescence of the protein. Thus, high specificity and sensitivity are ensured, and the quantity, activity and mechanism of various proteins can be analyzed in an easy and accurate manner.

  本发明涉及一种用于iFRET的探针及其使用。具体而言，本发明涉及一种新型iFRET探针、制备iFRET探针的方法、使用iFRET探针搜索靶蛋白特异性结合位点或具有结合位点的分子的方法，以及使用iFRET探针成像靶蛋白的方法。本发明的iFRET探针利用蛋白质中的氨基酸作为荧光给体，而不是传统的FRET方法。因此，仅使用一个荧光材料，其发射波长与蛋白质的内在荧光不同。因此，确保了高度的特异性和灵敏度，并且可以轻松准确地分析各种蛋白质的数量、活性和机制。
• PROBE FOR IFRET AND USAGE OF SAME
  申请人：Korea Research Institute Of Bioscience And Biotechnology

  公开号：EP2725357A2

  公开（公告）日：2014-04-30

  The present invention relates to a probe for iFRET and use thereof. Specifically, the present invention relates to a novel probe for iFRET, a method for preparing the probe for iFRET, a method for searching a target protein-specific binding site or a molecule having the binding site using the probe for iFRET, and a method for imaging the target protein using the probe for iFRET. The probe for iFRET according to the present invention utilizes an amino acid in a protein as a fluorescent donor, unlike the conventional FRET method. Therefore, only one fluorescent material is used, and its emission wavelength is distinct from the intrinsic fluorescence of the protein. Thus, high specificity and sensitivity are ensured, and the quantity, activity and mechanism of various proteins can be analyzed in an easy and accurate manner.

  本发明涉及一种 iFRET 探针及其用途。具体而言，本发明涉及一种新型 iFRET 探针、一种制备 iFRET 探针的方法、一种使用 iFRET 探针搜索目标蛋白质特异性结合位点或具有该结合位点的分子的方法，以及一种使用 iFRET 探针对目标蛋白质成像的方法。与传统的 FRET 方法不同，本发明的 iFRET 用探针利用蛋白质中的一个氨基酸作为荧光供体。因此，只需使用一种荧光材料，其发射波长与蛋白质的固有荧光不同。因此，可确保高特异性和高灵敏度，并可轻松准确地分析各种蛋白质的数量、活性和机理。
• Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2<i>H</i>-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor
  作者：Leonardo Pisani、Giovanni Muncipinto、Teresa Fabiola Miscioscia、Orazio Nicolotti、Francesco Leonetti、Marco Catto、Carla Caccia、Patricia Salvati、Ramon Soto-Otero、Estefania Mendez-Alvarez、Celine Passeleu、Angelo Carotti

  DOI：10.1021/jm9010127

  日期：2009.11.12

  In an effort to discover novel selective monoamine oxidase (MAO) B inhibitors with favorable physicochemical and pharmacokinetic profiles, 7-[m-halogeno)benzyloxy]coumarins bearing properly selected polar substituents at position 4 were designed, synthesized, and evaluated as MAO inhibitors. Several compounds with MAO-B inhibitory activity in the nanomolar range and excellent MAO-B selectivity (selectivity index SI > 400) were identified. Structure-affinity relationships and docking simulations provided valuable insights into the enzyme-inhibitor binding interactions at position 4, which has been poorly explored. Furthermore, computational and experimental studies led to the identification and biopharmacological characterization of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate 22b (NW-1772) as an in vitro and in vivo potent and selective MAO-B inhibitor, with rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. On the basis of this preliminary preclinical profile, inhibitor 22b might be viewed as a promising clinical candidate for the treatment of neurodegenerative diseases.
• Design, synthesis and biological evaluation of coumarin coupled nitroimidazoles as potential imaging agents
  作者：Nisha Saini、Raunak Varshney、Anjani K. Tiwari、Ankur Kaul、M. P. S. Ishar、Anil K. Mishra

  DOI：10.1039/c5ra17907f

  日期：——

  Solid tumors contain regions of hypoxia in comparison to normal tissues. The nitroimidazoles have shown great promise for targeting different types of cancers.

  实体肿瘤与正常组织相比，含有缺氧区域。硝基咪唑类化合物已显示出针对不同类型癌症的巨大潜力。